Shares of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) have been assigned a consensus rating of “Hold” from the ten analysts that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, six have issued a hold rating and three have assigned a buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $7.28.
A number of analysts recently issued reports on the stock. Maxim Group restated a “buy” rating and set a $7.00 target price on shares of Keryx Biopharmaceuticals in a research report on Monday, May 1st. ValuEngine upgraded shares of Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st. BidaskClub lowered shares of Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 25th. Zacks Investment Research lowered shares of Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, July 17th. Finally, Cowen and Company restated a “market perform” rating on shares of Keryx Biopharmaceuticals in a research report on Tuesday, July 25th.
COPYRIGHT VIOLATION WARNING: This piece was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this piece can be accessed at https://stocknewstimes.com/2017/08/10/keryx-biopharmaceuticals-inc-nasdaqkerx-receives-average-rating-of-hold-from-analysts.html.
Keryx Biopharmaceuticals (NASDAQ KERX) traded down 2.31% during mid-day trading on Friday, hitting $6.35. 725,778 shares of the stock traded hands. Keryx Biopharmaceuticals has a 12 month low of $4.03 and a 12 month high of $8.38. The company’s market cap is $754.06 million. The stock’s 50 day moving average is $7.24 and its 200-day moving average is $6.14.
Keryx Biopharmaceuticals (NASDAQ:KERX) last announced its earnings results on Thursday, July 27th. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.17) by $0.60. Keryx Biopharmaceuticals had a negative return on equity of 2,902.87% and a negative net margin of 431.89%. The firm had revenue of $15.10 million for the quarter, compared to analyst estimates of $14.51 million. During the same quarter last year, the business posted ($0.42) EPS. The firm’s revenue was up 62.4% compared to the same quarter last year. On average, equities research analysts anticipate that Keryx Biopharmaceuticals will post ($1.23) EPS for the current year.
Several institutional investors have recently made changes to their positions in the stock. Metropolitan Life Insurance Co. NY raised its position in shares of Keryx Biopharmaceuticals by 6.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 64,077 shares of the biopharmaceutical company’s stock worth $375,000 after buying an additional 3,994 shares during the period. Norges Bank bought a new position in shares of Keryx Biopharmaceuticals during the fourth quarter worth $9,973,000. Teachers Advisors LLC raised its position in shares of Keryx Biopharmaceuticals by 3.3% in the fourth quarter. Teachers Advisors LLC now owns 138,874 shares of the biopharmaceutical company’s stock worth $814,000 after buying an additional 4,402 shares during the period. Bank of Montreal Can bought a new position in shares of Keryx Biopharmaceuticals during the first quarter worth $434,000. Finally, Rice Hall James & Associates LLC raised its position in shares of Keryx Biopharmaceuticals by 3.0% in the first quarter. Rice Hall James & Associates LLC now owns 1,340,649 shares of the biopharmaceutical company’s stock worth $8,258,000 after buying an additional 39,656 shares during the period. Institutional investors own 57.06% of the company’s stock.
About Keryx Biopharmaceuticals
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
Receive News & Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
